{"analyses":[{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"98.72","ciUpperLimit":"0.84","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0005","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalMethod":"Stratified Cox Proportional hazard model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.59","upperLimit":"21.19","value":"8.41"},{"comment":"Insufficient number of events to calculate median value. Upper limit number not reached","groupId":"OG001","lowerLimit":"22.01","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo","id":"OG000","title":"Placebo"},{"description":"Nivolumab 240mg IV Q2W","id":"OG001","title":"Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants with PD-L1 expression ≥ 1%","reportingStatus":"POSTED","timeFrame":"approximately up to 48 months","title":"Disease Free Survival (DFS) in PD-L1 Expression ≥ 1% Population","type":"PRIMARY","unitOfMeasure":"Months"}